Baidu
map

BMC Pediatr: 儿童中早期抗生素接触与哮喘和过敏性鼻炎发展研究

2019-07-19 AlexYang MedSci原创

在过去的几十年中,儿科过敏性疾病的患病率增加迅速。最近的研究表明了过敏性疾病的增加与早期肠道微生物的失调相关。肠道微生物在出生时形成并且在出生后1年内很容易失调。早期的抗生素接触可能对肠道微生物的组成造成不良的影响,并造成生态失调,从而增加儿童患过敏性疾病的风险。最近,有研究人员进行了回顾性的图表分析,数据时间为2007年到2016年。入选的标准为在洛约拉大学医学中心(LUMC)出生且至少具有2次

在过去的几十年中,儿科过敏性疾病的患病率增加迅速。最近的研究表明了过敏性疾病的增加与早期肠道微生物的失调相关。肠道微生物在出生时形成并且在出生后1年内很容易失调。早期的抗生素接触可能对肠道微生物的组成造成不良的影响,并造成生态失调,从而增加儿童患过敏性疾病的风险。

最近,有研究人员进行了回顾性的图表分析,数据时间为2007年到2016年。入选的标准为在洛约拉大学医学中心(LUMC)出生且至少具有2次跟踪调查。研究人员还利用双变量逻辑回归统计分析研究了抗生素与疾病发展的关系。研究发现,在出生后1年内接触抗生素与哮喘具有显著的相关性(OR 2.66; C.I 1.11-6.40),但是与过敏性鼻炎不存在上述关系。另外,终生抗生素的使用与哮喘(OR 3.54; C. I 1.99-6.30)和过敏性鼻炎(OR 2.43; C. I 1.43-4.11)具有显著的相关性。

最后,研究人员指出,出生后1年内和终生使用抗生素与哮喘和过敏性鼻炎的发展显著相关。他们的结果支持了儿童应该选择保守治疗的观点。

原始出处:

Ni J, Friedman H, Boyd BC et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. BMC Pediatr. 05 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639175, encodeId=fd0d16391e5a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 13 09:19:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047138, encodeId=65fa204e13805, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Nov 26 06:19:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728052, encodeId=a6491e28052be, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 17:19:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974949, encodeId=d49819e494982, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 07 23:19:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369945, encodeId=4964369945b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jul 19 13:22:33 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639175, encodeId=fd0d16391e5a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 13 09:19:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047138, encodeId=65fa204e13805, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Nov 26 06:19:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728052, encodeId=a6491e28052be, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 17:19:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974949, encodeId=d49819e494982, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 07 23:19:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369945, encodeId=4964369945b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jul 19 13:22:33 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639175, encodeId=fd0d16391e5a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 13 09:19:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047138, encodeId=65fa204e13805, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Nov 26 06:19:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728052, encodeId=a6491e28052be, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 17:19:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974949, encodeId=d49819e494982, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 07 23:19:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369945, encodeId=4964369945b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jul 19 13:22:33 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2020-02-03 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639175, encodeId=fd0d16391e5a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 13 09:19:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047138, encodeId=65fa204e13805, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Nov 26 06:19:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728052, encodeId=a6491e28052be, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 17:19:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974949, encodeId=d49819e494982, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 07 23:19:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369945, encodeId=4964369945b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jul 19 13:22:33 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639175, encodeId=fd0d16391e5a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Oct 13 09:19:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047138, encodeId=65fa204e13805, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Nov 26 06:19:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728052, encodeId=a6491e28052be, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 17:19:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974949, encodeId=d49819e494982, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 07 23:19:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369945, encodeId=4964369945b7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jul 19 13:22:33 CST 2019, time=2019-07-19, status=1, ipAttribution=)]
    2019-07-19 phoebeyan520

    学习了

    0

相关资讯

Nat Med:中外科学家研究证实 寨卡病毒延迟儿童神经发育

美国加州大学洛杉矶分校和中国科学院遗传与发育生物学研究所等机构研究人员,报告了2015年至2016年巴西里约热内卢寨卡病毒大流行期间,感染寨卡病毒的孕妇生下的216名婴儿的神经发育情况,结果显示,约1/3的儿童神经发育或视力/听力异常。相关论文7月8日刊登于《自然—医学》。

儿童就医不害怕 儿童医疗辅助服务项目落地成都

对每个孩子来说,“去医院”都不是愉快的经历,特别是需要住院的患儿,还会产生与父母分离的焦虑以及与日常熟悉环境脱离的恐惧感;同时,很多家长也会因孩子生病住院饱受身心的双重考验。如何减轻患儿在就医过程中的恐惧心理,提升患儿及家长的就医感受,成为国家、医疗机构乃至全社会高度关注的课题。在此大背景下,以帮助患儿完成医疗程序为目标、以情绪疏导和行为引导为内容的儿童医疗辅助服务项目应运而生,并且逐步在业内推广

J Aller Cl Imm-Pract:叶酸代谢产物与儿童食物过敏的关系

在BBC儿童中,出生时UMFA浓度较高与FA的发生发展有关,这可能是由于子宫内合成叶酸的暴露增加或合成叶酸代谢的潜在遗传差异所致。

NEJM:C型利钠肽类似物治疗儿童软骨发育不全

由此可见,在软骨发育不全的儿童中,每日一次皮下注射Vosoritide与副作用相关,其通常看起来是轻微的。治疗导致年度生长速度持续增加长达42个月。

Int Arch Allergy Immunol:舌下螨免疫疗法在单敏和多敏过敏性鼻炎儿童中治疗长期效果研究

一些国外的研究表明了舌下免疫治疗(SLIT)具有长期的效果,但是关于SLIT在中国的长期效果数据仍旧缺乏。最近,有研究人员前瞻性的评估了2年SLIT粉尘螨滴剂治疗在单敏和多敏过敏性鼻炎(AR)儿童中的长期效果情况。研究包括了80名HDM敏感的AR儿童(年龄4-12岁)。其中有40名儿童同时在单敏(只对HDM敏感)和多敏分组中。研究跟踪调查的时间为7年。研究人员指出,共有31(77.5%)名单敏儿童

儿童近视治疗市场乱象丛生:“治愈”骗局多,眼镜店乱开处方

针灸按摩“降度镜”宣称治近视,打着“高科技”旗号推销治眼神器,眼镜店开“瞎处方”违规兜售保健品……记者调查发现,儿童近视治疗市场乱象丛生,近视“治愈系”骗局多,亟待加强整治力度。高科技眼罩、针灸按摩纯属“大忽悠”只要在近视患儿眼睛周围涂一层厚厚的药膏,戴上“降度镜”半小时,即可轻松治愈近视……湖南省人民医院眼视光医学中心王华教授遇到过很多陷入这种骗局的家长。他说,有商家声称“高科技眼罩”配合独家中

Baidu
map
Baidu
map
Baidu
map